Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
The Helix Laboratory Platform is the first whole-exome sequencing platform to receive do novo authorization by the agency and paves the way for others.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
